

- [54] Title: SUPPRESSION OF β -LYMPHOCYTES IN MAMMALS BY ADMINISTRATION OF ANTI- β -LYMPHOCYTE ANTIBODIES
- [75] Inventor (s): HARRY M. MEYER and MARTIN J. WEISS, both of New Jersey, U.S.A.
- [73] Assignee (s): AMERICAN CYANAMID COMPANY, of New Jersey, U.S.A. a corporation of Maine, U.S.A.
- [22] Filed: March 15, 1989
- [21] Application Serial No: 38332

FOREIGN APPLICATION PRIORITY DATA

- [31] Number (s) : 169,263
- [32] Date (s) : March 17, 1988
- [33] Country (ies) : U.S.A.
- [52] PH Class 424/1.1
- [51] Int. Class A61K 39/395; A61K 43/00, 45/00
- [58] Field of Search 424/1.1
- [56] Reference (s) Cited and/or Considered: None

[57] ABSTRACT

Selective suppression of B-lymphocytes in mammals is accomplished by treatment with an adequate amount to antibody of a mature β -lymphocyte surface marker.



30,691

26021

Suppression of B-Lymphocytes in Mammals

Abstract of the Disclosure

Selective suppression of B-lymphocytes in mammals is accomplished by treatment with an adequate amount to antibody of a mature B-lymphocyte surface marker.

Background of the Invention

5 The site-selective delivery of cytotoxic agents, radionuclides, toxins or pro-inflammatory substances to tumors by conjugation of these agents to monoclonal antibodies specific for tumor-associated antigens offers the promise of important advances in cancer diagnosis and therapy. At present the use of human antibodies is limited and therapeutic and diagnostic applications are not practical. Therefore, 10 it is necessary to resort to antibodies derived from appropriate animals - usually the mouse. Since these antibodies are foreign to the human an immune response is to be expected and indeed is often noted as discussed by J. W. Larrick and J. M. Bourla in Prospects for the Therapeutic Use of Human Monoclonal Antibodies, J. Biol. Responses Modifiers, 5, 379-393 15 (1986).

Moreover, antibodies may be formed in response to foreign proteins (e.g. toxins) coupled to the therapeutic antibody. Even with human or chimeric 20 (human constant plus mouse variable regions) antibodies an immune response is a possibility. This response involves the formation by the host's B-lymphocytes of antibodies to the administered antibodies or other foreign proteins as discussed by R. C. Kennedy et al in Scientific American, 225, 48 (1986). When they occur, such responses compromise the therapeutic approach since they neutralize the therapeutic antibody before it has had the opportunity to carry out its function. 25 In addition, there is also the possibility of serious hypersensitivity reactions which may endanger the patient as discussed by L. Chatenoud in The Immune Response Against Therapeutic Antibodies, Immunology Today, 7, 367-368 (1986) and M. L. Zoler in Monoclonal Antibodies: On the Verge of Therapeutic Reality? Medical World News, 92-108, June 9, 1986. In order to 30 minimize the immune response, a mammal can be treated



with a variety of known immunosuppressive agents, alone or in combination, such as corticosteroids, cyclosporin, cyclophosphamide and others. These agents, although partially effective, are non-selective and generally suppress many components of the immune system and consequently to obtain the desired suppression of the mammal's humoral response, serious and even life-threatening side-effects can occur as a result of the concomitant action against other immune system components. This invention provides a novel, specific and therefore more preferable procedure to temporarily suppress that component, and only that component, of the immune system which is responsible for the antibody response to foreign proteins, such as murine-derived antibodies, namely the B-lymphocytes.

Summary of the Invention

The invention is a therapeutic method which comprises administration to a mammal of a pharmaceutically effective amount(s) of one or more anti B-lymphocyte antibodies or fragments thereof, unmodified or conjugated to an appropriate radioisotope, cytotoxic agent or toxin or altered to elicit antibody mediated or cell mediated cytotoxicity. The antibody is administered in an amount sufficient to suppress the response of the B-lymphocytes to concurrent, subsequent, or prior administration to the mammal of diagnostic or therapeutic doses of, unmodified antibodies or antibody fragments, or conjugates thereof with therapeutic or diagnostic agents such as radioisotopes, toxins, cytotoxic agents, or the like; or to other therapeutic or diagnostic non-antibody foreign proteins. The invention includes immunosuppressive formulations. The invention also includes immunosuppressive diagnostic and therapeutic formulations.

Description of the Preferred Embodiments

5 The invention is a method to suppress the
response of B-lymphocytes in mammals to diagnostic or
therapeutic doses of unmodified antibodies, antibody
fragments or conjugates thereof with radioisotopes,
toxins or cytotoxic agents or other diagnostic or
therapeutic doses of non-antibody foreign proteins
comprising administering to a mammal one or more anti
B-lymphocyte unmodified antibodies or fragments thereof
10 or anti B-lymphocyte antibodies or fragments thereof
conjugated to a radioisotope, cytotoxic agent or toxin
or anti B-lymphocyte antibodies or fragments thereof
altered to elicit antibody or cell mediated
cytotoxicity in a pharmaceutically effective amount to
15 suppress the response of the B-lymphocytes to
concurrent, subsequent or prior administration to the
mammal of effective doses of diagnostic or therapeutic
unmodified antibodies, antibody fragments or conjugates
thereof with radioisotopes, toxins or cytotoxic agents
20 diagnostic or therapeutic doses of non-antibody or
foreign proteins.

The invention includes an immunosuppressive
formulation comprising one or more anti B-lymphocyte
unmodified antibody or fragments thereof or anti
25 B-lymphocyte antibodies or fragments thereof conjugated
to a radioisotope, cytotoxic agent or toxin or anti
B-lymphocyte antibodies or fragments thereof altered to
elicit antibody or cell mediated cytotoxicity and a
pharmaceutically suitable carrier.

30 The invention further includes
immunosuppressive diagnostic or therapeutic
formulations comprising diagnostic or therapeutic
unmodified antibodies, antibody fragments or conjugates
thereof with radioisotopes, toxins or cytotoxic agents;
35 or diagnostic or therapeutic non-antibody proteins and
and immunosuppressive anti B-lymphocyte unmodified
antibodies or fragments thereof or anti B-lymphocyte

antibodies or fragments thereof conjugated to a radioisotope, cytotoxic agent or toxin or anti B-lymphocyte antibodies or fragments thereof altered to elicit antibody or cell mediated cytotoxicity and a pharmaceutically suitable carrier.

5 Selective suppression of the B-lymphocytes can be accomplished by treatment with an adequate amount of antibody to a mature B-lymphocyte surface marker. Preferably, this antibody should recognize the mature B-lymphocyte and not the stem cell, thus
10 allowing for a later repopulation of B-lymphocytes by the stem cell. Such antibodies can be prepared readily by procedures well-known in the art. Antibodies to malignant B-lymphocytes, useful for the treatment of B-lymphocyte lymphoma, are often cross-reactive with
15 normal B-lymphocytes and also can be used for this purpose. Examples of such antibodies exist in the literature. For example, Epstein and co-workers describe the preparation of two such antibodies, termed Lym-1 and Lym-2, in Two New Monoclonal Antibodies,
20 Lym-1 and Lym-2, Reactive with Human B-Lymphocytes and Derived Tumors, with Immunodiagnostic and Immunotherapeutic Potential, Cancer Research, 47, 830-840 (1987); also note references cited in this paper to other anti B-lymphocyte antibodies. Although
25 these antibodies are of murine origin their repeated administration to humans is not precluded since the B-lymphocyte response to their murine aspect will be suppressed. Since it is possible that in some, if not in many or all cases, the B-lymphocyte population may
30 not all share the same surface marker, it may be necessary to utilize more than one antibody to effectively achieve the desired suppression of the B-lymphocyte response. This invention envisions the utilization of as many antibodies as necessary to
35 accomplish this goal.

5 This invention also envisions the use of unmodified ("naked") antibodies as well as antibodies conjugated with a suitable cytotoxic agent, toxin or radionuclide. Appropriate radioisotopes include ¹³¹I, ⁹⁰Y, and ⁶⁷Cu. Procedures for the preparation of iodinated antibodies are well-known in the art (see S. L. Mills et al., Hybridoma, 5, 265-275 (1986) and references cited therein) and such preparations can be carried out easily in hospital radiopharmacies. [FW ⁹⁰Y see L. C. Washburn et al., Nvel. Med. Biol. 13, 453-456 (1986) and M. Chinol Md D.J. Hnatowich J. Nvel. Med., 28, 1465-1470 (1987) and for ⁶⁷Cu see M. K. Moi et al., Analytical Biochemistry, 148, 249-253 (1985)]. For the purposes of this invention a preparation containing on average about one alpha or beta-emitting radioisotope for each antibody molecule would be preferred.

15 The antibody also can be conjugated by procedures described in the art with known cytotoxic drugs such as methotrexate, aminopterin, mitoxantrone, vincristine, vinblastine, doxorubicin and others, or plant toxins such as abrin, or ricin or the like or their ribosome-inactivating sub-units, or any other agents known to have cytotoxic properties.

25 In addition, this invention contemplates the use of genetically, enzymatically, or chemically altered antibodies which recognize B-lymphocytes, whereby the constant regions have been altered or replaced with domains which fix complement proteins or elicit target cell destruction by virtue of antibody-dependent cellular cytotoxicity (ADCC), thus activating the patient's own immune system.

35 In addition to cancer therapy, this novel modality would be similarly useful in conjunction with the use of therapeutic monoclonal antibodies in the treatment of diseases such as bacterial, viral, protozoal and other infections, endotoxic shock,

5 autoimmune diseases, progressive multiple sclerosis and
others. In the instance of organ transplant rejection,
treatment with the murine-derived anti-T lymphocyte
OKT-3 antibody is accompanied by a strong B-lymphocyte
response to the mouse antibody, which, at least in
part, compromises this approved clinically-useful
procedure [C. F. Shield II et al., Nephron 46: suppl.
1, 48-51 (1987)]. Use of the modality of this
invention in conjunction with OKT-3 antibody and the
10 like would enhance the efficiency of this procedure.

Example 1

An immunosuppressive formulation of Lym-1
antibody capable of suppressing the response of
B-lymphocytes and a pharmaceutically suitable carrier
15 is administered to a mammal. Following the method of
treatment of this example should result in the
selective suppression of B-lymphocytes.

Example 2

An immunosuppressive formulation of
20 ^{131}I -Lym-1 in a pharmaceutically acceptable carrier
(Example 8) is administered to a mammal. Following the
method of treatment of this example should result in
the selective suppression of B-lymphocytes allowing the
administration of multiple doses of murine-derived
antibodies for therapeutic purposes.

Example 3

An immunosuppressive formulation of
25 ^{131}I -Lym-1 in a pharmaceutically acceptable carrier
(Example 8) is administered to a mammal. Following the
method of treatment of this example should result in
30 the selective suppression of B-lymphocytes allowing the
administration of multiple doses of therapeutic
antibody conjugated to ricin A-chain.

Example 4

An immunosuppressive formulation of
35 ^{131}I -Lym-1 in a pharmaceutically acceptable carrier
(Example 8) is administered to a mammal. Following the

method of treatment of this example should result in the selective suppression of B-lymphocytes allowing the administration of multiple doses of therapeutic antibody conjugated to a derivative of vinblastin, vinorisdine or vindesin.

5

Example 5

A site-selective formulation of a therapeutic dose of antibody conjugated with methotrexate in a pharmaceutically suitable carrier is administered to a mammal. Then ¹³¹I-Lym-1 antibody in a pharmaceutically suitable carrier (Example 9) is administered to the same mammal. Following the method of treatment of this example should result in the site-selective delivery of the cytotoxic agent and the selective suppression of B-lymphocytes.

10

15

Example 6

A formulation containing murine derived anti-T cell OKT-3 antibody is administered to a mammal after an organ transplant. Then ¹³¹I-Lym-1 antibody in a suitable carrier (Example 8) is administered to the same mammal. Following the method of treatment of this example should enhance the efficiency of the OKT-3 antibody treatment.

20

Example 7

A formulation containing murine derived anti-T cell OKT-3 antibody is administered to a mammal after an organ transplant while concurrently administering ¹³¹I-Lym-2 antibody (prepared in the manner of Example 8) in a suitable carrier to the same mammal. Following the method of treatment of this example should enhance the efficiency of the OKT-3 antibody treatment.

25

30

35

Example 8

Iodination Procedure Preparation of ^{131}I -Lym Dosage

Formulation

- 5 1. All containers, chromatographic media, and tubing required for the procedure are sterilized.
2. Adjust Na^{131}I solution to pH of about 8.5 by addition of 0.1N HCl.
- 10 3. Centrifuge monoclonal antibody LYM-1 for injection.
4. Add LYM-1 to Na^{131}I solution at one to one molar ratio.
5. Add chloramine-T solution at a ratio of 1.25 mcg chloramine-T to 100 mcg LYM-1 and vortex.
- 15 6. React at 4°C for 10 minutes.
7. Quench reaction by addition of a sodium metabisulfite solution (at 2 to 1 molar ratio to chloramine-T).
8. Chromatograph on Biogel P-10/Dowex 1-X8 column.
- 20 9. Pass through a 0.2 micron filter.
10. Collect in a 50 ml vial; adjust ^{131}I activity to about 150 milliCURIES by withdrawal of excess solution; dilute to 50 ml with a phosphate buffered saline solution containing 5% human serum albumin.
- 25

A pharmaceutically suitable carrier for the formulations of this invention is sterile phosphate-buffered saline optionally containing about 5% human serum albumin, for example, see Example 9.

30

Example 9

LYM-1 FORMULATION

COMPOSITION

	<u>Component</u>	<u>Percent (w/w)</u>	<u>Quantity per Unit Dose (mg/10ml)</u>
5	LYM-1	1.0	10.0
	Sodium Phosphate, Monobasic USP	0.022*	0.22*
	Sodium Phosphate, Dibasic USP	0.119*	1.19*
10	Sodium Chloride USP	0.877	8.77
	Hydrochloric Acid USP or Sodium Hydroxide USP	**	**
15	Water for Injection qs ad v	-	10 ml

* Anhydrous basis.

**Added to adjust pH to approximately 7.2

20

25

30

35

30,691

WE CLAIM:

5 1. A method to suppress the response of B-lymphocytes in mammals to diagnostic or therapeutic doses of unmodified antibodies or antibody fragments; or of conjugates thereof with radioisotopes, toxins or cytotoxic agents; or of diagnostic or therapeutic doses of non-antibody foreign proteins comprising

10 administering to a mammal one or more

anti B-lymphocyte unmodified
antibodies or fragments thereof or

15 anti B-lymphocyte antibodies or fragments thereof conjugated to a radioisotope, cytotoxic agent or toxin or

20 anti B-lymphocyte antibodies or fragments thereof altered to elicit antibody or cell mediated cytotoxicity

25 in a pharmaceutically effective amount to suppress the response of the B-lymphocytes to concurrent, subsequent, or prior administration to the mammal of effective doses of the diagnostic or therapeutic unmodified antibodies, antibody fragments or conjugates thereof with radioisotopes, toxins or cytotoxic agents; or the diagnostic or therapeutic doses of non-antibody foreign proteins.

30

35 2. A method to suppress the response of B-lymphocytes in mammals to diagnostic or therapeutic doses of unmodified antibodies or antibody fragments;



or of conjugates thereof with radioisotopes, toxins or cytotoxic agents; or of diagnostic or therapeutic doses of non-antibody foreign proteins according to Claim 1 comprising

5

administering to a mammal one or more

anti B-lymphocyte unmodified
antibodies or fragments thereof

10

in a pharmaceutically effective amount to suppress the response of the B-lymphocytes to subsequent, concurrent, or prior administration to the mammal of effective doses of the diagnostic or therapeutic unmodified antibodies, antibody fragments or conjugates thereof with radioisotopes, toxins or cytotoxic agents; or of diagnostic or therapeutic doses of non-antibody foreign proteins.

15

20

3. A method according to Claim 2 wherein the anti B-lymphocyte antibody is Lym-1 or Lym-2.

25

4. A method according to Claim 2 wherein the anti B-lymphocyte antibodies are Lym-1 and Lym-2.

30

5. A method to suppress the response of B-lymphocytes in mammals to diagnostic or therapeutic doses of unmodified antibodies or antibody fragments; or of conjugates thereof with radioisotopes, toxins or cytotoxic agents; or of diagnostic or therapeutic doses of non-antibody foreign proteins according to Claim 1 comprising

35

administering to a mammal one or more

anti B-lymphocyte antibodies or
fragments thereof conjugated to a

radioisotope, cytotoxic agent or
toxin

5 in a pharmaceutically effective amount to suppress the
response of the B-lymphocytes to subsequent
administration to the mammal of effective doses of the
diagnostic or therapeutic unmodified antibodies or
antibody fragments; or of conjugates thereof with
radioisotopes, toxins or cytotoxic agents; or of the
10 diagnostic or therapeutic doses of non-antibody foreign
proteins.

6. A method according to Claim 5 wherein the
anti B-lymphocyte antibody is Lym-1 or Lym-2 conjugated
15 to ^{131}I .

7. A method according to Claim 5 wherein the
anti B-lymphocyte antibodies are Lym-1 and Lym-2, each
conjugated to ^{131}I .

8. The method according to Claim 5 wherein
20 the therapeutic antibody is an anti-melanoma antibody
conjugated to the ricin A-chain.

9. A method to suppress the response of
B-lymphocytes in mammals to diagnostic or therapeutic
doses of unmodified antibodies or antibody fragments;
or of conjugates thereof with radioisotopes, toxins or
cytotoxic agents; or of diagnostic or therapeutic doses
30 of non-antibody foreign proteins according to Claim 1
comprising

administering to a mammal one or more
35 anti B-lymphocyte antibodies or
fragments thereof altered to elicit

antibody or cell mediated
cytotoxicity

5 in a pharmaceutically effective amount to suppress the
response of the B-lymphocytes to subsequent, concurrent
or prior administration to the mammal of effective
doses of the diagnostic or therapeutic unmodified
antibodies, antibody fragments or conjugates thereof
with radioisotopes, toxins or cytotoxic agents; or of
10 the diagnostic or therapeutic doses of non-antibody
foreign proteins.

15 10. A method to suppress the response of
B-lymphocytes in mammals to multiple therapeutic doses
of anti T-lymphocyte antibody according to Claim 1.

20 11. A method according to Claim 10 wherein
the anti T-lymphocyte antibody is the OKT-3 antibody
and the anti B-lymphocyte antibody is Lym-1 or Lym-2
conjugated to ¹³¹I.

25 12. A method according to Claim 10 wherein
the anti T-lymphocyte antibody is OKT-3 antibody and
the anti B-lymphocyte antibodies are Lym-1 and Lym-2
each conjugated to ¹³¹I.

HARRY M. MEYER, JR.
MARTIN J. WEISS
(Inventors)

30

35